[Abstract Only] Randomized Trial: Ruxolitinib Cream for Treatment of Vitiligo
12 Jul, 2020 | 23:58h | UTCRuxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial – The Lancet
Related Commentary on Twitter
NEW—Treatment with ruxolitinib cream was associated with substantial repigmentation of vitiligo lesions up to 52 weeks of treatment, and all doses were well tolerated: finding from a randomised, controlled, phase 2 trial https://t.co/Td5nlsMcYI pic.twitter.com/CHvtspGstQ
— The Lancet (@TheLancet) July 10, 2020